Why on earth would anyone subscribe to this? 25 cents in 18 months is ridiculous. I cannot see any progress on any of their flimsy projects in the next 10 years, plus. My opinion only. No doubt Eyeover sees it differently, and will climb in!
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%